Chronic Hepatitis B
Female gender and low platelet counts favor hepatitis B response to lamivudine
Published in Hepatitis Weekly, August 1st, 2005
"Chronic hepatitis B (CHB) is an important cause of end stage liver disease and hepatocellular carcinoma. Controlled clinical trials indicate treatment with lamivudine results in positive clinical responses," scientists in the United States report.
"The study goal was to determine if the response to lamivudine treatment (hepatitis e antigen [HBeAg] loss, hepatitis B virus [HBV] DNA loss and alanine aminotransferase [ALT] reduction) differs according to pretherapy (pre-tx) ALT levels. This was a retrospective review of medical record data," said H.W. Hann and colleagues,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-08-01)
More Articles from Hepatitis Weekly
- Cancer Detection
The ANN/TM-GTP index accurately predicts recurrent liver cancer - Hepatitis C Therapy
Hepatitis C patients without spontaneous clearance respond to PEG-interferon - Oncology
Oral contraceptive use helps women survive liver cancer - Pediatric Hepatology
Lamivudine impairs glucose metabolism in children with chronic hepatitis B - Virology
Liver-specific interferon gamma expression controls hepatitis B in mice - Addiction Medicine
New findings in the area of addiction medicine detailed - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
